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Helminth infections are responsible for a considerable public health burden, yet the current drug arma-
mentarium is small. Given the high cost of drug discovery and development, the high failure rates and the
long duration to develop novel treatments, drug repurposing circumvents these obstacles by ﬁnding new
uses for compounds other than those they were initially intended to treat. In the present review, we
summarize in vivo and clinical trial ﬁndings testing clinical candidates and marketed drugs against schis-
tosomes, food-borne trematodes, soil-transmitted helminths, Strongyloides stercoralis, the major human
ﬁlariases lymphatic ﬁlariasis and onchocerciasis, taeniasis, neurocysticercosis and echinococcosis. While
expanding the applications of broad-spectrum or veterinary anthelmintics continues to fuel alternative
treatment options, antimalarials, antibiotics, antiprotozoals and anticancer agents appear to be producing
fruitful results as well. The trematodes and nematodes continue to be most investigated, while cestodal
drug discovery will need to be accelerated. The most clinically advanced drug candidates include the
artemisinins and meﬂoquine against schistosomiasis, tribendimidine against liver ﬂukes, oxantel
pamoate against trichuriasis, and doxycycline against ﬁlariasis. Preclinical studies indicate a handful of
promising future candidates, and are beginning to elucidate the broad-spectrum activity of some
currently used anthelmintics. Challenges and opportunities are further discussed.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
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Helminth infections caused by roundworms (nematodes) and
ﬂatworms (platyhelminths) comprise the greatest group of the
neglected tropical diseases (NTDs) (Hotez et al., 2006). An esti-
mated 11.5 million disability adjusted life years (DALYs) are attrib-
uted to intestinal nematode infections, schistosomiasis, lymphatic
ﬁlariasis, onchocerciasis, food-borne trematodiasis, cysticercosis
and echinococcosis (Murray et al., 2012). Most of the burden of
these diseases results from disability (rather than premature
death), inﬂuencing school attendance, child development and
overall economic productivity, thus resulting in disease driven
poverty traps (Hotez et al., 2006). In a recent special issue of the
Disease Clinics of North America (Zumla and Keiser, 2012), cestode
infestations (Brunetti and White, 2012), schistosomiasis (Gryseels,
2012), food-borne trematodiases (Fürst et al., 2012), ﬁlariases
(Knopp et al., 2012a) and soil-transmitted helminthiases (Knopp
et al., 2012b) were presented in great detail and hence for back-
ground information on these diseases, the reader is referred to
these excellent publications.
Preventive chemotherapy is the strategy of choice to control
schistosomiasis, soil-transmitted helminthiases, lymphatic ﬁlaria-
sis, onchocerciasis and food-borne trematodiases yet as empha-
sized in the following sections of this review, limited tools are
available to treat these infections. In addition, for many of the
available drugs, resistance is a threat since it has already developed
in veterinary medicine and many of the drugs have an imperfect
activity proﬁle. Yet clear targets have been set to eliminate
and control several of these diseases (http://www.unitingto
combatntds.org/downloads/press/london_declaration_on_ntds.
pdf). Hence research and development (R&D) to ﬁnd the next
generation of anthelmintics is indispensable. However, a recent
systematic assessment of databases of drug regulatory authorities
and the World Health Organization (WHO) as well as clinical trial
registries revealed a dry drug pipeline for NTDs, supported by the
fact that no new chemical entity had been approved for these dis-
eases in the past decade (Pedrique et al., 2013).
Drug repurposing (also termed re-proﬁling, re-tasking, thera-
peutic switching or drug repositioning) is the process of developing
new indications for existing, failed or abandoned drugs or
advanced clinical candidates (Sekhon, 2013). Drug repurposing is
a useful strategy to accelerate the drug development process due
to lower costs, reduced risk and decreased time to market due to
availability of preclinical data (Padhy and Gupta, 2011). This
enables not only pharmaceutical companies but also public-sector
researchers to engage in drug discovery and development efforts
(O’Connor and Roth, 2005), and hence might result in treatment
options for diseases almost exclusively addressed by public sector
researchers, such as the neglected tropical diseases. Over the past
years, a variety of drug-repurposing initiatives have been launched
with particular attention to neglected tropical and rare diseases
(Allarakhia, 2013), hence it is likely that these efforts will bear fruit
in the next years.The aim of the present article is to highlight the status of drug
repurposing for neglected helminth diseases. The focus is on the
state-of-the-art treatments and how drug repurposing has been
supplying the drug development pipeline for schistosomiasis, infec-
tions with major food-borne trematodes, Fasciola spp., Opisthorchis
spp. and Clonorchis sinensis, soil-transmitted helminthiasis, Strongy-
loides stercoralis, themajor human ﬁlariasis, lymphatic ﬁlariasis and
onchocerciasis, taeniasis, neurocysticercosis and echinococcosis.
Our review complements a recent article by Andrews and col-
leagues which summarized antiprotozoal drug repurposing for
major parasitic protozoal diseases including malaria, trypanosomi-
asis, and leishmaniasis (Andrews et al., 2014).
2. Schistosomiasis and food-borne trematodiases
2.1. Current treatment
Since its discovery in the 1970s, praziquantel has replaced
many other drugs as the sole treatment for a range of helmintic
infections. Praziquantel is effective against all three major species
of Schistosoma (S. mansoni, S. haematobium and S. japonicum), and is
the standard treatment against C. sinensis, Opisthorchis viverrini and
Opisthorchis felineus, and intestinal ﬂukes (Keiser and Utzinger,
2004; Utzinger and Keiser, 2004). It is administered orally, is safe,
and highly effective.
As mentioned above, preventive chemotherapy is the strategy
of choice to control schistosomiasis (WHO, 2006). This program
is expected to expand ten-fold to include the treatment of 235 mil-
lion people by 2018 (Knopp et al., 2013) which, on the one hand
may signiﬁcantly drive down morbidity and transmission but, on
the other hand, would exacerbate drug pressure, likely resulting
in resistance to praziquantel (Caffrey, 2007). Furthermore, prazi-
quantel still has deﬁciencies: it is inactive against the juvenile
stage of Schistosoma spp. and its (S)-enantiomer is inactive, a prob-
lem because at the moment, it is not separated from the (R)-enan-
tiomer in production and hence the tablets are large and bitter
(Stothard et al., 2013). Therefore, there is great motivation to seek
alternative medications.
In the case of fascioliasis, triclabendazole is the treatment of
choice (Keiser et al., 2005). Triclabendazole is safe and effective
against both the human and veterinary forms of the disease. How-
ever, there are two major setbacks: in veterinary medicine, tricla-
bendazole resistance has already been documented (Brennan et al.,
2007). Additionally, triclabendazole is not registered for use in
many nations, and is therefore not always available for the treat-
ment of human fascioliasis (Keiser et al., 2005).
2.2. Repurposed drugs
2.2.1. Antimalarials and their derivatives
The largest anthelmintic drug repurposing success story by far
has been the application of antimalarials against a wide variety
of trematode infections, as well as other broader applications.
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and the liver ﬂukes are based on the rationale that these ﬂukes
have the same blood-feeding characteristic as Plasmodium spp.,
and therefore share heme degradation mechanisms (Toh et al.,
2010). If antimalarials target this pathway, they may also be effec-
tive against blood-digesting ﬂukes. However, antimalarials have
shown activity also against the non-blood feeding intestinal ﬂukes
(Ingram et al., 2012b), not only indicating their broad-spectrum
activity, but also hinting at other mechanisms of action. As empha-
sized earlier, the use of antimalarials in de-worming programs
should be eyed with caution, as this could accelerate resistance
to these drugs. Nevertheless, since malaria and schistosome infec-
tions largely overlap geographically, the wide use of antimalarials
might be beneﬁcial in co-infected patients (Keiser and Utzinger,
2012).
2.2.1.1. Artemisinins. Artemisia annua (quinghao) has been used for
thousands of years in Chinese medicine for a wide range of ail-
ments, yet its antimalarial properties did not become known to
the wider world until the 1970s, despite its prevalence as a com-
mon herb (Tu, 2011). Artemisinin, the plant’s active ingredient, is
a sesquiterpene lactone, with a characteristic peroxide bridge that
is widely believed to be the active pharmacophore. Though potent,
its short half-life, poor bioavailability and the reliance on plant cul-
tivation spurred a search for semi-synthetic and completely syn-
thetic alternatives (Ho et al., 2014). The most widely used
artemisinin-derivatives are the ﬁrst-generation semi-synthetics
artesunate and artemether. Artemisinin-based therapies have
shown great efﬁcacy against Schistosoma spp., Fasciola spp., Opis-
thorchis spp. and C. sinensis, as summarized in previous reviews
(Keiser and Utzinger, 2007b, 2012; Utzinger et al., 2007). Brieﬂy,
artemether, artesunate and dihydroartemisinin (the active metab-
olite of all artemisinin compounds) share common antischistoso-
mal therapeutic characteristics. In vivo studies have
demonstrated that these artemisinins are highly effective against
juvenile infections and only moderately effective against adult
infections (Keiser and Utzinger, 2012; Li et al., 2014). This observa-
tion suggests that these drugs particularly show clinical beneﬁt
when used as prophylactic treatments. Indeed, as calculated by a
recent meta-analysis by Liu and colleagues, administration of mul-
tiple low doses of artemether or artesunate over a 1–2 week period
achieved a protection rate of 65–97% against schistosomiasis
japonicum (Liu et al., 2011). In addition, a decreased risk was
observed using artemether for the prevention of S. mansoni and
S. haematobium infections (Utzinger et al. 2000; N’Goran et al.
2003). Contradictory ﬁndings were obtained when these agents
were used in the treatment of chronic infections. While some stud-
ies reported high efﬁcacy, low to moderate cure rates (CRs) were
observed in other trials (Keiser and Utzinger, 2007a). However,
overall the therapeutic effect of artesunate, artemether or artemis-
inin based combination therapy (ACTs) against schistosomiasis
was inferior to praziquantel in clinical trials (Keiser and Utzinger,
2007a; Utzinger et al., 2010). Finally, the artemisinins often
showed synergistic effects with praziquantel in clinical trials, as
elucidated by two meta-analyses (Liu et al., 2011; Perez del Villar
et al., 2012).
The artemisinins have also been thoroughly characterized
against food-borne trematodes in in vivo studies. Artemether and
artesunate were both found to be very effective against the liver
ﬂukes Fasciola hepatica and C. sinensis, as well as the intestinal ﬂuke
Echinostoma caproni in the rodent infection models, achieving com-
plete worm clearance (Keiser et al., 2006a,c,d), though lower worm
burden reductions (WBRs) were achieved in the O. viverrini ham-
ster infection model (66% and 78% for artemether and artesunate,
respectively, administered as a single oral dose of 400 mg/kg)
(Keiser et al., 2006d). Artemether and artesunate administered tosheep naturally infected with F. hepatica also achieved signiﬁcant
WBRs (91.3% at a dose of 140 mg/kg intramuscular (i.m.) and
91.9% at a dose of 40 mg/kg i.m. respectively), though embryotox-
icity and toxicity were of potential concern (Keiser et al., 2008a,
2010e).
Studies with the artemisinins have progressed to clinical trials
in Fasciola-infected patients: in central Vietnam, patients sub-
jected to a 10-day treatment course with artesunate, adminis-
tered daily at a dose of 4 mg/kg, were less likely to report
abdominal pain at hospital discharge than patients treated with
a standard oral dose of 10 mg/kg triclabendazole. However,
3 months post-treatment, clinical and serological response rates
were lower among artesunate recipients compared to triclaben-
dazole-treated patients (Hien et al., 2008). This result mirrors
an exploratory Phase 2 trial conducted in Egypt, where chroni-
cally infected patients treated with 6  80 mg and 3  200 mg
artemether only achieved CRs of 35 and 6%, respectively (Keiser
et al., 2011). Finally, low CR and egg reduction rate (ERR) of 4%
and 32% were also observed after administration of artesunate
(10 mg/kg in 3 split doses) to school-aged children infected with
O. viverrini (Soukhathammavong et al., 2011).
2.2.1.2. Synthetic peroxides. The success of the semi-synthetic
artemisinins along with their pharmacologic draw-backs moti-
vated the creation of fully synthetic derivatives in antimalarial
drug discovery, the most investigated of these being the synthetic
ozonides. The antimalarial OZ439 is currently in Phase 2 clinical
trials (Wells, 2013). Two synthetic trioxolanes in particular have
been widely investigated as potential anthelmintics- OZ78 and
OZ288- whose trematocidal activity has been reviewed by Keiser
and Utzinger (2007b). The review highlights the major in vivo stud-
ies which reveal interesting properties of these two compounds.
First, their activity is comparable to those of the artemisinins and
they exhibit the same increased in vivo activity against juvenile
S. mansoni as compared to adult worms in mice and in hamsters.
Second, in S. mansoni in vivo models, the adult WBR is affected
by the rodent model, achieving only moderate WBRs in the mouse
but high WBRs in the hamster model. However follow-up studies
indicated similarly signiﬁcant activity of OZ78 against S. japonicum
juvenile and adult infection in hamsters, mice and rabbits, and of
OZ277 in hamsters (Xiao et al., 2011, 2012). Interestingly, the
ozonide OZ418 was recently found to be active against both juve-
nile and adult worms in the mouse S. mansoni infection model, and
the adult S. haematobium hamster infection model (Keiser et al.,
2012a), as well as moderately active against 7 day-old and adult
S. japonicum- infected mice (Xue et al. 2014)- a result which shows
that further modiﬁcations of the aryl ozonides can yield promising
compounds.
With regard to the food-borne trematodes, in vivo activity of
OZ78 against the liver ﬂukes F. hepatica and C. sinensis and the
intestinal ﬂuke E. caproni is very high but studies with O. viverrini
showed no activity at all (Keiser and Utzinger, 2007c). Importantly,
in follow-up studies, OZ78 was found to be effective against tricla-
bendazole-resistant F. hepatica (100% WBR at oral dose of 100 mg/
kg) (Keiser et al., 2007a). Oddly, the high activity of the OZs against
F. hepatica could not be repeated in naturally-infected sheep,
regardless of the administration route (Keiser et al., 2010b;
Meister et al., 2013). This discrepancy could potentially be
explained by pharmacokinetic differences observed in rat and
sheep, as discussed by Meister and colleagues (Meister et al.,
2013).
Where OZ78 failed to treat F. hepatica in sheep, MT04 suc-
ceeded. MT04 is another synthetic peroxide, identiﬁed in the
search for more effective analogues, which was found to have a
92% WBR and a 99% ERR in naturally infected sheep (Zhao et al.,
2010; Wang et al., 2011; Meister et al., 2013).
Table 1
Trematocidal in vivo drug candidates.
Adult infection Juvenile infection
Parasite Drug Host animal Dose (mg/kg) WBR (%) Dose (mg/kg) WBR (%) References
Schistosoma mansoni Dihydroartemisinin Mouse 3  200–400 60–70 3  200–400 89–90 Li et al. (2012)
OZ78 Mouse 400 52 200 95 Xiao et al. (2007)
Hamster 200 85 100 83 Xiao et al. (2007)
OZ288 Mouse 400 0 200 82 Xiao et al. (2007)
Hamster 200 72 100 84 Xiao et al. (2007)
OZ418 Mouse 400 96 200 100 Keiser et al. (2012a)
Tribendimidine Mouse 400 0 n.d. n.d. Keiser et al. (2007b)
Imatinib Mouse 3  1000 0 n.d. n.d. Katz et al. (2013)
Miltefosine Mouse 5  20 95 5  20 76 Eissa et al. (2011a)
Nilutamide Mouse 400 85 50–400 5–36 Keiser et al. (2010d)
BTP-iso Mouse 300 55 n.d. n.d. El Bialy et al. (2013)
Clorsulon Mouse 1–3  5 88–98 n.d. n.d. Mossallam et al. (2007)
Anisomycin Mouse 100 0 n.d. n.d. Abdulla et al. (2009)
Lasalocid sodium Mouse 100 41–44 n.d. n.d. Abdulla et al. (2009)
Diffractic acid Mouse 10–40 0 n.d. n.d. Abdulla et al. (2009)
Gamboic acid Mouse 100 0 n.d. n.d. Abdulla et al. (2009)
Niclosamide Mouse 100 0 n.d. n.d. Abdulla et al. (2009)
Rafoxanide Mouse 50 50–56 n.d. n.d. Abdulla et al. (2009)
Schistosoma haematobium OZ418 Hamster 400 86 n.d. n.d. Keiser et al. (2012a)
Schistosoma japonicum Dihydroartemisinin Mouse 300 61 300 65 Li et al. (2011)
OZ78 Hamster 200 70–94 200 73–81 Xiao et al. (2011)
Rabbit 15 423 n.d. n.d. Xiao et al. (2012)
Mouse 200–600 67–80 400 75 Xiao et al. (2012)
Fasciola hepatica OZ78 Rat 100 100 100 100 Keiser et al. (2006b)
Sheep 50–100 0 n.d. n.d. Keiser et al. (2010b), Meister et al. (2013)
MT04 Sheep 100 92 n.d. n.d. Meister et al. (2013)
Tribendimidine Rats 800 0 n.d. n.d. Keiser et al. (2007b)
Clonorchis sinensis OZ78 Rat 300 99 300 79 Keiser and Utzinger (2007a)
Tribendimidine Rat 150 98 n.d. n.d. Keiser et al. (2007b)
Opisthorchis viverrini OZ78 Hamster 600 77 n.d. n.d. Keiser and Utzinger (2007a)
Tribendimidine Hamster 400 63 n.d. n.d. Keiser et al. (2007b)
WBR indicates worm burden reduction in relation to untreated control animals. n.d. denotes a lack of data.
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discovery as an antimalarial dates to around the same time as
the artemisinins. Its antischistosomal activity was revealed in
2008 and was thoroughly covered in a review by Xiao et al.
(2013). This review highlights some excellent antischistosomal
properties of meﬂoquine. First, it is active against all three major
Schistosoma spp. and against both the juvenile and adult stages, a
characteristic that neither praziquantel nor the artemisinins pos-
sess. Second, it causes severe morphological damage to the ﬂuke
and acts independently of the host immune response. Third, initial
results from clinical trials were promising; meﬂoquine- artesunate
achieved an ERR of 95% against S. haematobium in school-aged chil-
dren (Keiser et al., 2010c). In addition, pregnant women who used
meﬂoquine as intermittent preventive treatment for the preven-
tion of malaria showed signiﬁcantly higher CRs and ERRs against
S. haematobium than women treated with sulfadoxine-pyrimeth-
amine (Basra et al., 2013). Moreover, meﬂoquine-related arylmeth-
anols also show antischistosomal activity in vivo (Ingram et al.,
2012a).
The effectiveness of meﬂoquine against food-borne trematodes
was brieﬂy reviewed by Keiser et al. (2010a). This review high-
lighted that meﬂoquine is not active against F. hepatica nor C. sin-
ensis, but interestingly, meﬂoquine was active against juvenile and
adult O. viverini in a hamster infection model, achieving a WBR of
89% and 96% respectively, following a single oral dose of 300 mg/kg
(Keiser et al., 2009a). However, meﬂoquine failed to produce an
effect against O. viverini in clinical trials (Soukhathammavong
et al., 2011). In a later study, meﬂoquine yielded signiﬁcant results
against C. sinensis infection in a rat model (when given at multiple
dosages) and Paragonimus westermani infection in a dog model, butthe results were not better than a treatment with praziquantel
(Xiao et al., 2010).
2.2.2. Tribendimidine
Also originating from China, tribendimidine is a Chinese anthel-
mintic drug which has a similar activity proﬁle against the soil-
transmitted helminths as albendazole (high activity against Ascaris
lumbricoides and hookworms but only moderate activity against
Trichuris trichiura) (Xiao et al., 2013). Besides its broad range of
antinematodal activity, tribendimidine has demonstrated tremato-
cidal activity in vivo against C. sinensis and O. viverrini (Keiser et al.,
2010a; Xiao et al., 2013). A recent randomized open-label trial in
Guangxi, PR China presented moderate CRs (44% following a single
dose of 400 mg/kg and 58% following 400 mg/kg administered
once daily for 3 days) and high ERR (98–99%), similar to praziquan-
tel. Tribendimidine compared favorably to praziquantel with
regards to appearance of adverse events (Qian et al., 2013). Simi-
larly, tribendimidine cured 19 of 24 patients infected with O. viver-
rini and achieved an ERR of 99% (Soukhathammavong et al., 2011).
Further studies with tribendimidine are currently ongoing (e.g.
dose-ﬁnding, pharmacokinetic studies) in O. viverrini-infected
patients in Laos with the ultimate goal of developing an alternative
opisthorchicidal drug.
To offset eventual resistance to praziquantel, using tribendimi-
dine in combination with praziquantel is an attractive option.
However, a recent study showed that praziquantel-tribendimidine
administered to O. viverrini-infected hamsters, though achieving
synergistic effects in vitro, had antagonistic effects in the hamster
murine model (Keiser et al., 2013a). Further studies are required
to shed light on this phenomenon. In contrast, in the C. sinensis
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interactions with 150 mg/kg praziquantel (Keiser et al., 2009b).
2.2.3. Other compounds
The most recent in vivo antitrematodal candidates come from a
range of sources and ﬁelds, including cancer research, though
expanding veterinary drug applications continues to be popular.
The discoveries are described below and summarized in Table 1.
2.2.3.1. S. mansoni. A (well-funded) cancer drug pipeline provides a
cornucopia of compounds. Dissous and Grevelding (2011) recently
explored the potential of repurposing cancer drugs, speciﬁcally
protein kinase inhibitors, towards schistosomiasis. The principal
rationale was the identiﬁcation of select protein kinases as being
essential to schistosome development and the subsequent identiﬁ-
cation of certain cancer drugs as inhibitors of these kinases. How-
ever, most of the drugs discussed were only inhibitors of egg
development and had little effect on the adult worms themselves.
The one exception was imatinib (Gleevec), a successful anti-leuke-
mia agent, which was shown to be lethal to adult worms in vitro at
high concentrations (Beckman and Grevelding, 2010). However,
imatinib was ineffective in an S. mansoni infection model (Table 1)
(Katz et al., 2013) which is not surprising, as the drug is highly
bound to alpha-1-acid glycoprotein (Soo et al. 2010).
Nonetheless, two anticancer agents have shown promising
in vivo activity. Miltefosine, an alkylphospholipid, was initially
developed to combat cutaneous metastasis of mammary carcino-
mas (van Blitterswijk and Verheij, 2013). As discussed in a comple-
mentary review by Andrews et al. (2014), it has also recently been
licensed to treat leishmaniasis- a protozoan that also has cutane-
ous manifestations, though this drug treats both the visceral and
cutaneous forms (Dorlo et al., 2012). Recently, it has shown
in vivo activity in the S. mansoni mouse model at various stages
of infection. Administered at 20 mg/kg for ﬁve consecutive days,
commencing either on the day of infection (schistosomula stage),
21 days p.i. or 42 days p.i., miltefosine showed WBRs of 91%, 76%
and 95%, respectively (Eissa et al., 2011a). A recent study by Eissa
and colleagues also demonstrated its ovicidal, larvicidal and mol-
luscicidal activity and its in vitro activity against S. haematobium
adult worms (Eissa et al., 2011b). Interestingly, our own studies
have shown that miltefosine was only moderately active against
newly transformed schistosomula (NTS) of S. mansoni (unpub-
lished ﬁndings).
The antiandrogen, nilutamide, blocks the binding of testoster-
one to the androgen receptor and was initially marketed for the
treatment of metastatic prostate cancer (Akaza, 2011). Recently,
we have tested it in the S. mansoni mouse model since related
hydantoin derivatives studied at Hoffmann-La Roche had intrigu-
ing antischistosomal properties (Link and Stohler, 1984) – a single
400 mg/kg oral dose achieved a WBR of 85% and an even higher
WBR was observed when given in combination with praziquantel
(Keiser et al., 2010d). However, nilutamide did display a stage spe-
ciﬁc effect – it was only moderately active against the juvenile
stage (Keiser et al., 2010d).
The advantages and disadvantages of using cancer drugs in the
treatment of helmintic diseases should be carefully weighed. On
the one hand, there is a great deal of effort to minimize toxic effects
of cancer drugs due to their long treatment course. If a cancer drug
is deemed safe when administered over a long period, there is a
good chance it is also safe as an anthelmintic, where treatment is
annual or twice annual (if part of regular preventive chemotherapy
programs) but short (i.e. single dose). However, due to the severity
and life threatening state of many cancers, the beneﬁt of taking the
drugs may outweigh potential severe adverse events. Thus, just
because a drug is approved for cancer treatment, does not mean
it is without signiﬁcant adverse events. Yet a drug used in preven-tive chemotherapy programs must have an excellent tolerability
proﬁle.
Extending the application of veterinary anthelmintics continues
to be a source of human anthelmintic candidates. Abdulla et al.
(2009) showed that rafoxanide, a salicylanilide derivative and a
veterinary anthelmintic, caused a 50–56% WBR in mice at a single
oral dose of 50 mg/kg. This compound was identiﬁed from a screen
of a commercially available FDA-approved library. This same
screen also identiﬁed anisomycin, lasalocid sodium, diffractic acid,
gamboic acid and niclosamide as hits for in vivo testing in the S.
mansoni mouse model. Unfortunately, these drugs failed to reduce
worm burden in vivo, the exception being lasalocid sodium which
caused a WBR of 41–44% when administered at 100 mg/kg orally.
Rafoxanide was not originally in the library, but due to
niclosamide’s excellent in vitro proﬁle (but poor in vivo results),
rafoxanide was tested as well, as it is structurally related to niclo-
samide. Clorsulon (a veterinary ﬂukicidal drug) caused a WBR in S.
mansoni-infected mice of 88%, 96% and 98% when treated with
either a single, double or triple dose of 5 mg/kg one week apart
starting from the 4th week postinfection (Mossallam et al.,
2007). Yet in our own studies only moderate activity against NTS
were observed in vitro when the NTS were incubated with 10 lM
clorsulon for 72 h (unpublished observations).
Another re-purposing strategy is to increase the anthelmintic
spectrum of activity through slight modiﬁcation of the molecule.
For example, BTP-Iso, a novel benzimidazole (in the same family
as triclabendazole) was recently investigated as an antischistoso-
mal. At a dose of 300 mg/kg given to S. mansoni-infected mice,
BTP-Iso showed statistically signiﬁcant higher reductions
(p < 0.01) in female (77%), male (35%), and total worms (55%) in
comparison with the control group (El Bialy et al., 2013).
2.2.3.2. F. hepatica. Two fasciocidal drugs were moved directly into
clinical testing, without previous publications of in vivo studies. In
Iran, 46 patients who were positive for Fasciola 3 months after tri-
clabendazole treatment were given 1.5 g/day metronidazole orally
for three weeks. Two months after end of therapy, stool exams
became negative in 35 patients (81%), of which 31 patients (72%)
presented both negative serology and stool exams. At 12 months,
28 patients were examined and all were negative (Mansour-
Ghanaei et al., 2003).
Nitazoxanide, a thiazolide derivative and a pyruvate ferredoxin
oxireductase inhibitor, has a broad spectrum of activity. The US
Food and Drug Administration (FDA) approved nitazoxanide in
2002 for the treatment of diarrhea caused by Cryptosporidium spe-
cies and Giardia intestinalis in pediatric patients 1–11 years of age,
and in 2004 for its use in adults (Hemphill et al., 2006). Two clinical
trials elucidated nitazoxanide’s fasciocidal effects. In northern
Peru, a double-blind placebo-controlled trial showed moderate
effects in children and adults: a 7-day course of nitazoxanide
resulted in CRs of 60% in adults and 40% in children (Favennec
et al., 2003). In the Atlixco municipality in Mexico, a study carried
out in 50 Mexican schoolchildren showed nitazoxanide to be effec-
tive against light F. hepatica infections. Children diagnosed with
fascioliasis were administered nitazoxanide at 7.5 mg/kg body
weight, every 12 hours over seven days. The efﬁcacy against fasci-
oliasis was 94% and 100% after ﬁrst and second treatment courses,
respectively. Its efﬁcacy was also very high against protozoan and
intestinal helminths (Zumaquero-Rios et al., 2013). However, this
second study did not have a control group, and therefore could
not be compared to a placebo or treatment with triclabendazole.
Given these somewhat contradictory ﬁndings, larger randomized
control trials should be conducted to elucidate the role of nitazox-
anide in the treatment of fascioliasis.
Myrrh has been marketed as an antischistosomal, though its
actual effect is controversial (Abdul-Ghani et al., 2009; Yakoot,
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94% CR, 2 and 3 months after treatment (Abo-Madyan et al., 2004),
the overall consensus based on bench and ﬁeld publications is that
it is ineffective as a fasciocidal agent (Botros et al., 2009; Keiser
et al., 2010a).
In the veterinary ﬁeld, the benzimidazoles are often used as
broad-spectrum anthelmintics, as discussed further in the soil-
transmitted helminths section below. In livestock, the use of oxfen-
dazole has previously been restricted to the treatment of round-
worm, strongyloides and pinworm infection. However, very
recently, it was demonstrated that it has potent anti-ﬂukicidal
activity: 100% WBR was achieved after a single oral dose of
30 mg/kg was given to F. hepatica infected pigs (Ortiz et al. 2014).
3. Soil-transmitted helminthiasis and strongyloides
3.1. Current treatment
The two benzimidazoles, albendazole and mebendazole, as well
as pyrantel pamoate and levamisole are the four available treat-
ments against soil-transmitted helminths, marketed between
1966 (pyrantel pamoate) and 1980 (albendazole) (Keiser and
Utzinger, 2010; WHO, 2013). These drugs are widely used (in
2010, 328million childrenwere treatedwith albendazole ormeben-
dazole (Anonymous, 2012)) since, as mentioned, the current strat-
egy to control morbidity due to the most common soil-transmitted
helminths (A. lumbricoides, T. trichiura and the hookworm species
Ancylostoma duodenale and Necator americanus) is by regular treat-
ment of at risk populations (WHO, 2006, 2011). The limitations of
these drugs are widely known. Brieﬂy, using a single dose regimen
they all are very efﬁcacious against A. lumbricoides, yet for the treat-
ment of hookworm infections only albendazole produces satisfying
CRs,while all drugs achieve poor CRs against infectionswith T. trich-
iura (Keiser and Utzinger, 2008). As no new anthelmintic drugs are
on the horizon, repurposing of existing drugs is an essential strategy
to improve treatment of soil-transmitted helminths, particularly
T. trichiura infections (Keiser andUtzinger, 2008;Olliaro et al., 2011).
The current drug of choice against S. stercoralis infections is iver-
mectin, which is widely used inmass drug administration programs
to combat lymphatic ﬁlariasis (Knopp et al., 2012a). A single dose of
200 lg/kg results in a CR of 88% against S. stercoralis (Keiser and
Utzinger, 2010). The drug has the disadvantages that it is not
licensed for treating S. stercoralis infections in several countries
(e.g. Switzerland, Germany, Great Britain), that the ideal dosage
schedule of ivermectin has yet to be evaluated, and that it can cause
harmful and dangerous treatment effects in individuals co-infected
with Loa loawhich is an insect-borne ﬁlarial infection (Bisofﬁ et al.,
2013; Greaves et al., 2013). People not tolerating ivermectin can
alternatively use albendazole, which is inferior compared to iver-
mectin regarding ERRs and CRs; however, it still achieves satisfac-
tory efﬁcacy (Keiser and Utzinger, 2010; Knopp et al., 2012a). In
addition, mebendazole achieves CRs and ERRs of 67–98% against S.
stercoralis when given in multiple doses (Musgrave et al., 1979;
Shikiya et al., 1990, 1991; Zaha et al., 2000). Of note, even though
ivermectin is not listed as an essential drug against soil-transmitted
helminths (WHO, 2013), several studies have shown that by com-
bining ivermectin with the standard drug albendazole or mebenda-
zole, the efﬁcacy against soil-transmitted helminths (especially
against T. trichiura) can be improved signiﬁcantly (a summary of tri-
als is presented in Keiser et al. (2012b)).
3.2. Repurposed drugs
3.2.1. Drugs evaluated in clinical testing
3.2.1.1. Nitazoxanide. Nitazoxanide, mentioned above for its proto-
zoan and fasciocidal properties, showed (in manufacturer-ﬁnancedtrials) very high CRs against A. lumbricoides, T. trichiura, S. stercoral-
is and even against A. duodenalewhen the drug was given in multi-
ple doses (Romero Cabello et al., 1997; Abaza et al., 1998; Juan
et al., 2002; Diaz et al., 2003). The drug also demonstrated superior
activity than the standard drugs in in vitro screening against
Trichuris muris (Tritten et al., 2012). However, a recent clinical trial
using a single dose of 1000 mg nitazoxanide could not conﬁrm the
initial results obtained in earlier trials and in the laboratory. Nita-
zoxanide achieved low CRs and ERRs (7% and 13%, respectively)
against T. trichiura in school-aged children on Pemba, Tanzania.
Additionally the drug was slightly less well tolerated compared
to standard treatment and hence nitazoxanide was not recom-
mended as an alternative treatment against soil-transmitted hel-
minthiasis (Speich et al., 2012). Of note, within the same trial,
the efﬁcacy of a single dose nitazoxanide (1000 mg) against intes-
tinal protozoa was also only moderate (Speich et al., 2013).
3.2.1.2. Oxantel pamoate. Oxantel pamoate, a veterinary drug
which was introduced on the market in 1974, revealed high efﬁ-
cacy against T. trichiura in a number of exploratory trials (Garcia,
1976; Lee et al., 1976; Lee and Lim, 1978). The drug was only revis-
ited recently, more than three decades later. Laboratory studies
demonstrated a signiﬁcantly higher activity of oxantel pamoate
compared to the benzimidazoles, levamisole or pyrantel pamoate
against T. muris in vitro and in vivo (Keiser et al., 2013b). A random-
ized controlled double blind trial recently conﬁrmed the high efﬁ-
cacy of oxantel pamoate (20 mg/kg) against T. trichiura (26% CR and
93% ERR). Hence oxantel pamoate-albendazole, due to its broad
spectrum of activity could be useful in the control of soil-transmit-
ted helminthiasis (Speich et al., 2014). Further studies have been
planned with the ultimate goal of elucidating the potential of add-
ing oxantel pamoate to the current drug armamentarium.
3.2.1.3. Tribendimidine. A large phase 2 trial in Côte d’Ivoire con-
ﬁrmed the excellent activity of tribendimidine against hookworm
and A. lumbricoides (N’Goran et al. under review). Following prom-
ising results with tribendimidine against Strongyloides ratti in the
rat model (Keiser et al., 2008b) an exploratory trial in China docu-
mented a CR of 55% in patients infected with S. stercoralis
(Steinmann et al., 2008).
3.2.1.4. The benzimidazoles. The benzimidazoles are a large family,
widely used in veterinary medicine, and not only include albenda-
zole and mebendazole (and the fasciocidal drug triclabendazole
mentioned earlier) but also ﬂubendazole, fenbendazole, oxfendaz-
ole, thiabendazole and oxibendazole (Olliaro et al., 2011). In addi-
tion, oxfendazole and cambendazole are promising broad
spectrum benzimidazoles used in veterinary medicine, which have
not yet been tested in humans. The benzimidazoles have a broad
spectrum of activity including whipworms, roundworms and
hookworms. For example, multiple doses of thiabendazole have
similarly high efﬁcacy against S. stercoralis as compared to iver-
mectin, however the drug was less tolerated (Gann et al., 1994;
Zaha et al., 2000; Bisofﬁ et al., 2011). Clinical trials conducted with
ﬂubendazole, fenbendazole, oxibendazole and thiabendazole
against soil-transmitted helminths and S. stercoralis are summa-
rized in Table 2.
3.2.2. Compounds in early clinical testing and potential veterinary
drugs
An excellent summary of potential drug development candi-
dates for human soil-transmitted helminthiasis has recently been
provided by Olliaro and colleagues (Olliaro et al., 2011).
Four promising compound classes are worth highlighting. First,
emodepside is a cyclic depsipeptide and a broad-spectrum veteri-
nary anthelmintic used for companion animal gastrointestinal
Table 2
Drugs tested in clinical trials against soil-transmitted helminths (See below-mentioned references for further information).
ecnerefeRetarnoitcuderggEetareruCesoDstneitapforebmuNdetsetgurD
Oxantel pamoate T. trichiura: 12-122 10-25 mg/kg  T. trichiura: 57-93% T. trichiura: 90-96% (Lee et al., 
1976) 
A. lumbricoides: 53 
T. trichiura: 10-26
10-20 mg/kg A. lumbricoides: 0%
T. trichiura: 77-100% 
)6791,aicraG(
 79 A. lumbricoides 
114 T. trichiura 
113 Hookworm 
20 mg/kg A. lumbricoides: 10%
T. trichiura: 26% 
Hookworm: 11% 
A. lumbricoides: 28%
T. trichiura: 93% 
Hookworm: 39% 
(Speich et al., 
2014) 
Nitazoxanide A. lumbricoides: 33-144 
T. trichiura: 9-86
7.5 mg/kg (500 mg to adults, 200 mg to 
children under 12 years) every 12 hours for 
3 consecutive days 
A. lumbricoides: 48-100% 
T. trichiura: 56-78% 
A. lumbricoides: 99.7-100% 
T. trichiura: 99.5-99.6% 
(Romero 
Cabello et al., 
1997) 
A. lumbricoides: 155 
T. trichiura: 29 
Hookworm: 46 
S. stercoralis: 36 
500 mg to adults, 200 mg to children 4 to 
11 years, and children 1 to 3 years 100 mg 
every 12 hours for 3 consecutive days 
A. lumbricoides: 95% 
T. trichiura: 86% 
Hookworm: 96% 
S. stercoralis: 94% 
(Abaza et al., 
1998) 
A. lumbricoides: 35 
T. trichiura: 18 
S. stercoralis: 6 
200 mg to children 4 to 11 years, and 100 
mg to children 1 to 3 years every 12 hours 
for 3 consecutive days 
A. lumbricoides: 89% 
T. trichiura: 89% 
S. stercoralis: 83%
A. lumbricoides: 99.9% 
T. trichiura: 99.8% 
(Juan et al., 
2002) 
A. lumbricoides: 8 
T. trichiura: 136 
Hookworm: 12 
1000 mg single dose A. lumbricoides: 63%
T. trichiura: 7% 
Hookworm: 67% 
T. trichiura: 13% 
(Speich et al., 
2012) 
Oxibendazole A. lumbricoides: 196 
T. trichiura: 178 
Hookworm: 340 
15 mg/kg/day for 3 days  A. lumbricoides: 93-98% 
T. trichiura: 67-71% 
Hookworm: 70-81% Hookworm: 98-99% 
(Huang et al., 
1990) 
Fenbendazole A. lumbricoides: 2-7 
T. trichiura: 6-17 
Hookworm: 5-31 
1 g and 1.5 g as single doses and 2 x 500 
mg over 24 hours 
A. lumbricoides: 60-100% 
T. trichiura: 65-100% 
Hookworm: 8-26% 
dnahcurB(
Haas, 1976) 
A. lumbricoides: 2 
T. trichiura: 14 
Hookworm: 18 
S. stercoralis: 14 
6 x 600 mg each 12 hours A. lumbricoides: 100% 
T. trichiura: 93% 
Hookworm: 89% 
S. stercoralis: 29% 
-zehcnaS(
Carrillo and 
Beltran-
Hernandez, 
1977) 
A. lumbricoides: 31 
T. trichiura: 28 
Hookworm: 18 
30-50 mg/kg A. lumbricoides: 84% 
T. trichiura: 29% 
Hookworm: 83% 
A. lumbricoides: 97% 
T. trichiura: 38% 
Hookworm: 82% 
(Rim et al., 
1981) 
Flubendazole A. lumbricoides: 3-5 
T. trichiura: 4-16 
Hookworm: 27-60 
2 x 300 mg (spaced by 12 or 24 hours)  A. lumbricoides: 100% 
T. trichiura: 38-100% 
Hookworm: 30-82% 
A. lumbricoides: 100% 
T. trichiura: 43-100% 
Hookworm: 88-96% 
(Bunnag et al., 
1980) 
T. trichiura : 19 100 mg twice a day for 3 days T. trichiura: 89% T. trichiura : >99% (Yangco et al., 
1981) 
A. lumbricoides: 33-47 
T. trichiura: 32-52 
200-600 mg, 300 x 2 mg A. lumbricoides: 90-97%
T. trichiura: 17-65% 
A. lumbricoides: 98.7-99.6%
T. trichiura: 91-95% 
(Kan, 1983) 
A. lumbricoides: 43-47 500 mg or 200 mg A. lumbricoides: 86-89% A. lumbricoides: 97-98% (de Silva et 
T. trichiura: 43-47 T. trichiura: 19-26% T. trichiura: 42-54% al., 1984) 
Thiabendazole S. stercoralis: 103 25 mg/kg twice a day for 3 days S. stercoralis: 79% (A.A. et al., 
2003) 
S. stercoralis: 92 25 mg/kg twice a day for 2 days S. stercoralis: 52% (Bisoffi et al., 
2011) 
S. stercoralis: 19 50 mg/kg/day twice a day for 3 days S. stercoralis: 89% (Gann et al., 
1994) 
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2011). It showed high activity against Trichuris spp., Ancylostoma
spp. and other nematodes in in vitro and in vivo studies (Harder
and von Samson-Himmelstjerna, 2002; Altreuther et al., 2009).
Moreover, the closely related PF1022A was potent in clearing
T. muris infections in mice at various stages of infection (Kulke
et al. 2014). In vivo studies on Haemonchus contortus have shown
that it has a different mode of action than the benzimidazoles
and ivermectin (von Samson-Himmelstjerna et al., 2005) hence
the drug will likely be active against parasites resistant to the
benzimidazoles and ivermectin.
Second, doramectin which belongs to the avermectins, showed
high efﬁcacy against S. ransomi, S. papillosus, T. suis and A. suum in
pigs (Stewart et al., 1996; Yawzinski et al., 1997) as well as against
Trichuris spp. in cattle (Jones et al., 1993; Saeki et al., 1995). Dora-
mectin showed even more favorable results against nematodes
compared to ivermectin, which could be explained by its lower
clearance and higher bioavailability (Lumaret et al., 2012). The clo-
sely related milbemycin family is also a potent drug class. Milbe-
mycin oxime has proven to be efﬁcacious against Ascaris spp.,
hookworm and Trichuris spp. in cats and dogs (Blagburn et al.,
1992; Catton and Van Schalkwyk, 2003). On the other hand only
low ERRs were found against T. trichiura in baboons (Reichard
et al., 2007).
Third, moxidectin is another commercially available broad-
spectrum antiparasitic from the veterinary ﬁeld (Reinemeyer andCleale, 2002). It is a semisynthetic methoxime derivative of natu-
rally occurring nemadectin with a novel mode of action (Awasthi
et al., 2013). Moxidectin showed high efﬁcacy in several in vivo
studies (i.e. in cattle, swine, sheep) against Ascaris spp., Trichuris
spp. and Strongyloides spp. (Bauer and Conraths, 1994; Coles
et al., 1994; Stewart et al., 1999; Reinemeyer and Cleale, 2002;
Ranjan and DeLay, 2004; Lyons et al., 2006).
Finally, from a completely different medical arena, cyclosporine
A is an immunosuppressive agent which is commonly used for
organ transplantation (Cohen et al., 1984). Its antischistosomal
properties were ﬁrst described in 1981 (Bueding et al., 1981) fol-
lowed by studies against S. stercoralis in dogs and S. ratti in rats
(Armson et al., 1995). Treatment with cyclosporine A seems to be
of beneﬁt in cases of opportunistic, possibly life threatening infec-
tions of S. stercoralis activated by immunosuppression (Schad,
1986).4. Filariasis
4.1. Current treatment
Though ﬁlariasis is a collection of diseases, the three major
control programs target lymphatic ﬁlariasis (Global Program to
Eliminate Lymphatic Filariasis) or onchocerciasis (African Program
for Onchocerciasis Control and the Onchocerciasis Elimination
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programs is mass drug administration. Regardless of the disease,
the recommended treatments are limited: ivermectin, albendazole
and diethylcarbamazine (DEC), ivermectin being the most widely
recommended drug. The use and status of these drugs, including
their limitations, have recently been reviewed by Katiyar and
Singh (2011). Brieﬂy, resistance to ivermectin has already been
documented and its administration to onchocerciasis patients co-
infected with loaiasis results in severe adverse events (Kamgno
et al., 2007). Albendazole’s efﬁcacy is heavily debated and DEC is
contraindicated in patients with onchocerciasis (Katiyar and
Singh, 2011). Additionally, the treatment regimens required for
these drugs in order to fully stop transmission are long: according
to current control guidelines, ivermectin or DEC-albendazole need
to be administered once a year for 5 years to interrupt LF transmis-
sion (Anonymous, 2009, 2014). The long treatment schedule is
partly because all three drugs predominantly act on microﬁlaria
only (the larvae shed by the adult worms), with DEC showing some
adult stage activity (Dreyer et al., 2006). This latter point is prob-
lematic, as the adult stage still survives in the host, ready to shed
more microﬁlaria once the drugs are absent from the host, contin-
uing to cause pathology in onchocerciasis patients and also contin-
uing the transmission cycle. Thus, new drug candidates should
necessarily target adult worms as well. Additionally, as all ﬁlaria-
sis-causing nematodes (except L. loa) carry with them the endo-
symbiotic Wolbachia bacteria necessary for the parasite’s
development, efforts have been made to target these bacteria.
4.2. Drugs targeting Wolbachia
Amongst the new antiﬁlarial drugs, doxycycline is the most
studied. It is a broad-spectrum antibacterial and antiprotozoal
whose effects against Wolbachia are considered a breakthrough
in antiﬁlarial treatment (Katiyar and Singh, 2011). In onchocercia-
sis patients, a treatment regimen of 100 mg of doxycycline per day
for 6 weeks slowly eliminatedWolbachia and resulted in long-term
embryogenesis block of the adult worms (Hoerauf et al., 2003). The
death of Wolbachia also leads to macroﬁlaricidal effects, as adults
worms extracted from LF patients treated with 200 mg of doxycy-
cline per day for 4 weeks were found to be either sterile or dead
(Debrah et al., 2007). Findings by Taylor and colleagues also
showed macroﬁlaricidal effects in LF patients, though the same
level of potency could not be observed in onchocerciasis patients
(Taylor et al., 2005; Hoerauf et al., 2008b). In addition, doxycycline
is potentially microﬁlaricidal as well, as shown in LF patients trea-
ted with 100–200 mg per day for 6 weeks (Supali et al., 2008).
Doxycycline, given prior to antiﬁlarial treatment, appears to be
more effective in suppressing microﬁlaremia in bancroftian ﬁlaria-
sis over the long term than the standard treatments alone, while
also resulting in fewer severe adverse events (Turner et al.,
2006). LF symptoms could also be reduced by doxycycline, regard-
less of active ﬁlarial infection as demonstrated in a trial in Ghana
(Mand et al., 2012). This symptomatic alleviation also extends to
LF patients who presented with hydrocele (Debrah et al., 2009).
The effects of doxycycline administered in combination with
the standard drugs have also been characterized. For example, a
combination of doxycycline and albendazole was far more effective
at suppressing circulating microﬁlaria than doxycycline or alben-
dazole alone (nearly 100% suppression vs. 69% and 89%, respec-
tively when checked at day 365 post-treatment) and even
succeeded in completely clearing 42% of patients of microﬁlaremia
(Gayen et al., 2013). Different trials also assessed doxycycline/iver-
mectin and found that the combination was more effective than
ivermectin or doxycycline alone (Masud et al., 2009; Turner
et al., 2010). Similarly, a 21-day course of doxycycline at 200 mg
administered orally to LF patients in Orissa, India, followed by asingle 6 mg/kg dose of DEC was effective at completely clearing
microﬁladermia. Interestingly, the co-administration of doxycy-
cline followed by DEC was also effective at clearing adult worm
nests, and less effective when the doxycycline treatment was
shortened to 10 days (Mand et al., 2009).
Doxycycline was even found to be effective against Mansonella
perstans, one of two agents that cause serous cavity ﬁlariasis. In a
randomized open-label trial in Mali, 97% and 75% of M. perstans
patients treated with 200 mg doxycycline for 6 weeks were found
to be amicroﬁlaremic at 12 and 36 months post-treatment, respec-
tively. This ﬁnding is very signiﬁcant as the current standard treat-
ments are not effective against M. perstans (Coulibaly et al., 2009).
Last but not least, given that L. loa is the only ﬁlarial nematode
that does not possess Wolbachia endosymbionts, the use of Wolba-
chia-targeting antibiotics is a possible safe alternative for the treat-
ment of this disease. Doxycycline was already shown to be safe in
onchocerciasis patients co-infected with loaisis (Wanji et al., 2009;
Turner et al., 2010), but its long treatment course leaves room for
short-course therapy innovations.
Considering the importance of a potent anti-Wolbachia treat-
ment, there is ongoing research to also elucidate the effects of
other potent broad-spectrum antibiotics on Wolbachia. Rifampicin
was found to be effective in reducingWolbachia bacteria, as well as
embryogenesis and microﬁlaria production in a small number of
onchocerciasis patients, though not as efﬁciently as doxycycline
(Specht et al., 2008). However a short-course therapy of 5 days rif-
ampicin was documented to be completely ineffective (Richards
et al., 2007). Meanwhile azithromycin was observed to be only
marginally effective against Wolbachia and showed no effect on
the worms in onchocerciasis patients in Ghana (Hoerauf et al.,
2008a). In another study, oxytetracycline (the parent compound
of doxycycline) had macroﬁlaricidal properties in cattle infected
with Onchocerca ochengi, however this success has yet to be trans-
lated to human treatment (Nfon et al., 2007).
4.3. Drugs targeting the worms
As mentioned above, drugs effective against the ﬁlarial adult
stage should be investigated with high priority. The potential of
the benzimidazole ﬂubendazole, a veterinary drug used to treat
gastrointestinal nematode infection, as a pre-clinical macroﬁlari-
cide candidate for preventive treatment of onchocerciasis and lym-
phatic ﬁlariasis is currently being studied in a project lead by the
Drugs for Neglected Diseases initiative (DNDi). These investigations
have been reviewed by Mackenzie and Geary (2011). In the late
1980s and early 1990s, ﬂubendazole was shown to be macroﬁlari-
cidal against a variety of ﬁlariases-causing agents in vivo and even
in a clinical trial for onchocerciasis (Dominguez-Vazquez et al.,
1983; Van Kerckhoven and Kumar, 1988; Franz et al., 1990). Inter-
estingly, it has no microﬁlaricidal effects (Van Kerckhoven and
Kumar, 1988), which indicates that it could be safe for L. loa co-
infected patients as well. The drug is, however, very poorly orally
absorbed and hence the current focus of the project lead by DNDi
is to improve the drug’s bioavailability. A new cyclodextrin formu-
lation is currently being investigated with mixed results: while it
achieved higher plasma concentrations when administered orally
to Echinococcus granulosus-infected mice, no signiﬁcant pharmaco-
kinetic effects were observed when it was administered to sheep
via the intraruminal nor the intraabomasal route (Ceballos et al.,
2009, 2012).
Nonetheless, other drugs on the horizon continue to target
microﬁlaria while also having some effects on the adult stage.
Unsurprisingly, moxidectin has shown potent microﬁlaricidal
effects and long term sterilization of females. Furthermore, early-
stage clinical trials have shown that it is safe and well tolerated
in humans in doses of 3–36 mg and has a longer half-life than
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evaluated in ongoing Phase 2 and 3 clinical trials via a partnership
between APOC, TDR and Wyeth (Taylor et al., 2009; Babalola,
2011). Nonetheless, tolerability studies are needed to conﬁrm that
moxidectin is safe in patients co-infected with L. loa and whether
the drug is efﬁcacious against ivermectin-resistant ﬁlaria.
Other anthelmintics tested include the above mentioned cyclic
depsipeptides, emodepside and PF1022A, and levamisole.
Emodepside showed potent microﬁlaricidal effects and even some
macroﬁlaricidal effects (but not against Brugia malayi) in vivo
(Zahner et al., 2001), hence there is great interest in the potential
of emodepside as a novel antiﬁlarial (http://r4d.dﬁd.gov.uk/PDF/
Outputs/DNDI/evolutions_of_dndi_portfolio.pdf). With regards to
levamisole, though previous studies from the 1980s showed it
had no signiﬁcant treatment effect for LF or onchocerciasis patients
(Awadzi et al., 1982; McMahon, 1981), the drug was revisited in a
clinical trial in 2004 where levamisole was given alone (2.5 mg/kg)
or co-administered with ivermectin or albendazole. Here as well, it
proved to be ineffective, alone or in combination (Awadzi et al.,
2004).
Nitazoxanide, mentioned earlier in this review, and its metabo-
lite tizoxanide were tested against B. malayi worms in vitro and
in vivo. The drugs were lethal to adult worms at 20 lg/ml and sig-
niﬁcantly decreased microﬁlaria release at 5 lg/ml. However, they
were ineffective against Wolbachia and eventually were shown to
be ineffective in clearing the worms in vivo (Rao et al., 2009).
Considering the success of antimalarials against trematodes, as
well as the co-endemicity of malaria and many helmintic diseases,
it is always tempting to test antimalarials on other worms as well.
Recently, an open randomized control trial investigated the effects
of the antimalarials quinine, chloroquine, amodiaquine and artesu-
nate, based on previous in vivo successes or case studies, on
patients infected with L. loa. However, none of the treatments were
found to be effective (Kamgno et al., 2010).
5. Cestode infections
5.1. Current treatment
Niclosamide, originally developed as a molluscicide, was intro-
duced in 1959 as the ﬁrst synthetic drug against taeniasis, charac-
terized by an excellent therapeutic index and high efﬁcacy (WHO/
FAO/OIE, 2005). It is a poorly water soluble halogenated salicylan-
ilide with a low bioavailability, which is an advantage since a sys-
temic action is not desired (Pearson and Hewlett, 1985; WHO/FAO/
OIE, 2005). Approximately one decade later, in 1972, the taenicidal
activity of praziquantel, an acylated isoquinoline-pyranzine, was
discovered jointly by Bayer AG and E. Merck (Andrews et al.,
1983). Both drugs are still the recommended ﬁrst line treatments
against intestinal cestodes including Taenia solium, Taenia saginata,
Diphyllobothrium spp. and Hymenolepis nana (WHO/FAO/OIE,
2005). Praziquantel, which is well absorbed from the intestine, pre-
sents additional activity against T. solium cysticerci located in the
host’s tissues (i.e. central nervous system, subcutaneous tissue,
and the eye). A single oral dose of praziquantel is highly effective
against taeniasis; nevertheless multiple treatment courses over
2 weeks are recommended for uncomplicated cysticercosis.
Albendazole, is also recommended for the treatment of (neuro)-
cysticercosis and is generally more active than praziquantel
(Sotelo et al., 1988, 1990; Takayanagui and Jardim, 1992; WHO/
FAO/OIE, 2005). Regardless, therapy for neurocysticercosis needs
to be individualized depending on the patient’s state of disease.
Anthelmintics, surgery, and symptomatic treatment with analge-
sics, corticosteroid drugs, and antiepileptic drugs, to relieve head-
ache, perilesional inﬂammation and seizures, are the main pillars
of the therapeutic approach (Carpio, 2002; Garcia et al., 2011).Surgical resection of the entire parasitic lesion is indicated in all
operable cases of cystic and alveolar echinococcosis. Puncture-
aspiration-injection-re-aspiration (PAIR) treatment is applied in
inoperable cases of cystic echinococcosis: cysts are punctured
and exposed to protoscolicidal substances (i.e. ethanol 95%) for at
least a quarter of an hour (WHO, 1996). Chemotherapy is key to
preventing secondary echinococcosis and to reducing the risk of
re-occurrence following surgery (Brunetti et al., 2010). Mebenda-
zole and albendazole are both recommended for the treatment of
echinococcosis. The albendazole dose regimen is more convenient
because its phase-1 metabolite, albendazole sulfoxide, also exhib-
its metacestodicidal properties and thus the drug disposition is
greater than for mebendazole (Ingold et al., 1999). Praziquantel
itself possesses less pronounced activity against echinococcosis
than albendazole. Combination treatment of praziquantel and
albendazole seems sensible, because both drugs display a different
mechanism of action and praziquantel increases the bioavailability
of albendazole sulfoxide when the two are given together (Cobo
et al., 1998; Kern, 2006; Garcia et al., 2011). Nonetheless, insufﬁ-
cient clinical data are available to provide treatment recommenda-
tions for this combination (Pawłowski, 2001; Bygott and Chiodini,
2009).
5.2. Repurposed drugs
5.2.1. Taeniasis and neurocysticercosis
The food and drug administration (FDA) approved nitazoxanide,
mentioned several times earlier in this review, as an antiprotozoal
agent against Cryptosporidium species and Giardia intestinalis in
2002 (Rossignol, 2009). Its chemical structure stems from the taen-
icide niclosamide and therefore, unsurprisingly, activity was
reported against T. saginata and H. nana infections in the 1980s
(Table 3) (Rossignol and Maisonneuve, 1984). Hence, nitazoxanide
is not a genuine example of a repurposed drug for taeniasis; still its
strong taenicidal activity makes it attractive for off-label use in
cases where patients do not respond to praziquantel or niclosa-
mide (Vermund et al., 1986; Lateef et al., 2008). Similarly, quina-
crine (mepacrine), which is an ancient antimalarial agent and
antigiardial drug, can be used to treat niclosamide-tolerant T. sag-
inata infections (Gardner et al., 1996; Koul et al., 2000).
The recent promising results achieved with tribendimidine
against O. viverrini and C. sinensis liver ﬂuke infections (see above)
inspired further exploration of its anthelmintic activity proﬁle
against cestodes. In an open-label randomized clinical trial, includ-
ing 15 patients infected with Taenia spp., a single oral dose of
200 mg (5–14 year old children) or 400 mg (P15 years) tribendim-
idine resulted in a CR of 67%. Due to diagnostic challenges and the
relatively small numbers of patient enrolled in the study, the
authors pointed out that the observed cestocidal effect of triben-
dimidine should rather be recognized as an indication of possible
activity rather than as a proof-of-concept (Steinmann et al.,
2008). A distinct anticestodal potential of tribendimidine was dem-
onstrated in mice infected with Hymenolepis microstoma, where a
triple dose of 50 mg/kg tribendimidine, given over three consecu-
tive days, achieved a WBR of more than 95% (Kulke et al., 2012).
No cestocidal effect was observed however, when mice were trea-
ted with deacetylated amidantel. This result is somehow unex-
pected as deacetylated amidantel is supposed to be the major
active metabolite of tribendimidine, hence further studies are
required (Xiao et al., 2009; Yuan et al., 2010).
Paromomycin (Humatin) is an aminoglycoside antibiotic with
activity against gram-negative and various gram-positive bacteria.
It is marketed to decrease bacterial load in the gut in hepatic coma,
and for the treatment of amoebiasis and giardiasis. Recently, it has
been licensed in India for leishmaniasis therapy (Davidson et al.,
2009). In the 1960s the taenicidal activity of paromomycin was
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where co-infected patients shed segments of T. saginata (Salem
and el-Allaf, 1969). In a follow-up clinical study it was demon-
strated that daily treatments for 1–3 days with 30–50 mg/kg
paromomycin resulted in a success rate of 89–100% against
T. saginata. In addition, an efﬁcacy of approximately 90% was
observed against H. nana following a 30 mg/kg single or double
dose of paromomycin (Salem and el-Allaf, 1969).
Tamoxifen is a ﬁrst generation selective estrogen receptor mod-
ulator (SERM), which acts as an antagonist on estrogen receptors in
breast tissue, while possessing an agonistic effect in other tissues. It
is used as an adjuvant for breast cancer and the palliative treatment
ofmetastatic or locally advancedmammacarcinoma (denHollander
et al., 2013). It has been demonstrated that estradiol plays an essen-
tial role in regulating the asexual reproduction of Taenia crassiceps
cysticerci in mice, possibly by interfering with the host’s cellular
immune response (Terrazas et al., 1994), and as a result, tamoxifen
was tested against T. crassiceps cysticerci. Tamoxifen reduced the
parasite load by 80% and 50% in female andmalemice, respectively.
In addition, loss ofmotility and reduced reproduction could be dem-
onstrated in vitro (Vargas-Villavicencio et al., 2007). A follow-up
study showed that tamoxifen decreased the intestinal establish-
ment of T. solium in hamsters by approximately 70%. Moreover,
tamoxifen induced morphological changes: the recovered tape-
worms appeared like scolices without strobilar development and
consequently showed an 80% reduction in length (Escobedo et al.,
2013). Yet the taenicidal and cysticidal potential of tamoxifen has
not been evaluated in humans and livestock.
Metrifonate is an organophosphorous compound applied as an
insecticide and veterinary anthelmintic. In humans it has been,
for example, for the treatment of schistosomiasis (Holmstedt
et al., 1978). A case report published in 1981 about a man with a
heavy cutaneous cysticercosis infection, described that two treat-
ment courses of metrifonate at 10 mg/kg/day for six days were able
to clear about 75% of the nodules and reduced the size of the
remaining ones. Nevertheless, the observed adverse drug events
caused by metrifonate’s unspeciﬁc cholinesterase inhibition were
so strong that atropine had to be given to relieve the symptoms
(Tschen et al., 1981).
5.2.2. Echinococcosis
In vitro and in vivo studies indicate that Echinococcus multilocu-
laris and E. granulosus can be included in the broad activityTable 3
Drugs tested in clinical trials against the major cestodes (Taenia and Echinococcus).
Drug Parasite Number of patients Dose
Nitazoxanide T. saginata
H. nana
22
18
25 mg/k
50 mg/k
T. saginata 18 children
34 adults
(niclosamide and
praziquantel-resistant
infections)
20 mg/k
500 mg
14 years
Echinococcus spp. (in
combination with
albendazole)
5 500 mg
Mepacrine
(quinacrine)
T. saginata 86 1 g p.o.
Tribendimidine Taenia spp. 15 200 mg
14 years
(P15 ye
Paramomycin T. saginata
H. nana
145
49
1–5 day
30 mg/k
Chlorhexidine
gluconate
E. granulosis 30 0.04% in
p.o denotes oral treatment, i.g. denotes treatment via a nasogastric tube, CR stands forspectrum of nitazoxanide. In vitro treatment of E. multilocularis
metacestodes with nitazoxanide lead to morphological and ultra-
structure alterations and inhibited larval growth, while E. granulo-
sus protoscoleces and metacestodes suffered deleterious effects as
well (Stettler et al., 2003; Walker et al., 2004; Reuter et al., 2006).
Subsequent in vivo experiments showed that a combination of
nitazoxanide and albendazole reduced parasite weight by about
4 times in the murine model (Stettler et al., 2004). A good effect
was observed in patients with disseminated cystic echinococcosis
on affected soft tissue, muscles, or viscera, who received nitazoxa-
nide additionally to the standard albendazole chemotherapy (with
or without praziquantel). Nevertheless, nitazoxanide shows no
effect on chronic and extensive body lesions (Perez-Molina et al.,
2011).
A 3-month treatment coursewith the anticancer drugs daunoru-
bicin, idarubicin, cytarabine, and ﬂudarabine did not affect the size
and contents of the echinococcus cysts in a patient suffering from
acute leukemia and cystic echinococcosis of the liver. The antifungal
agent amphotericin B was additionally applied within the chemo-
therapy schedule, but did not show parasitocidal activity against E.
granulosus cysts either (Ali et al., 2005). However, in vitro data sug-
gest that amphotericin B effectively inhibits the growth of E. multi-
locularis metacestodes (Reuter et al., 2003b). Amphotericin B is
also able to halt parasite growth in E.multilocularis-infected patients
and might therefore play a role as salvage treatment, when resis-
tance or intolerance to benzimidazoles occurs (Reuter et al., 2003a).
The anthelmintic agent ivermectin was tested against E. multi-
locularis in hamsters with intraperitoneal inoculation of protosco-
lices, and in rats with transportal inoculation of protoscolices.
The drug showed no effect in either case (Inaoka et al., 1987). In
addition, in vitro results conﬁrmed that ivermectin is also ineffec-
tive against E. multilocularis larvae (Reuter et al., 2006).
The spectrum of activity of antimalarials, such as meﬂoquine or
the artemisinins, was also assessed against echinococcosis.
Meﬂoquine presented a dose dependent activity against metaces-
todes in vitro, although a reduction of the parasite weight in
E. multilocularis-infected mice was only achieved by intraperito-
neal meﬂoquine administration and not with oral treatments
(Kuster et al., 2011). Artesunate and dihydroartemisinin, however,
had no effect against E. multilocularis in vivo (Spicher et al., 2008),
despite excellent in vitro activity. Furthermore, in vitro incubation
of E. multilocularis larvae with artemether did not induce destruc-
tion of parasite vesicles (Reuter et al., 2006).Outcome References
g
g
100% CR
100% CR
Rossignol and
Maisonneuve
(1984)
g p.o. (children 5–14 years);
twice daily for 3 days p.o. (>
)
98% CR Lateef et al.
(2008)
/12 hours for 3–24 months 40% improvement (2
patients improved)
Perez-Molina
et al. (2011)
or i.g. 94% Koul et al. (2000)
p.o. single dose (children 5–
) 400 mg p.o. single dose
ars)
67% CR Steinmann et al.
(2008)
s with 30–50 mg/kg
g single or double dose
89–100% CR
90% CR
Salem and el-Allaf
(1969)
intracystic injection 100% death of cystic
protoscolices
Topcu et al.
(2009)
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Figure 1. Sources of compounds for anthelmintic repurposing. A summary of the
ﬂelds from which the repurposed drugs discussed in this review are sourced. Only
successful drugs and drug candidates were included. ‘‘Extended applications’’ refers
to drugs that were already anthelmintics but whose activity was discovered to
extend to a broader range of helminth species.
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solution (0.5%) are considered to be scolicidal agents for PAIR
treatment with relatively low risk according to the WHO
(1996). Efforts were made to discover more potent scolicidal
agents to reduce the recurrence rate following PAIR and surgical
interventions. For instance, chlorhexidine gluconate, which is a
commonly available, inexpensive, and non-toxic antiseptic agent,
proved to be highly active at a concentration of 0.04% following
intracystic injection (Topcu et al., 2009). Moreover, in vitro data
conﬁrm that intracystic albendazole sulfoxide injections at con-
centrations of 50–100 lg/ml are highly scolicidal and additional
studies in rabbits indicate that this treatment lacks biliary and
systemic toxicity (Erzurumlu et al., 1998; Adas et al., 2009).
Recently, a water-soluble albendazole sulfoxide salt was devel-
oped (Bayverm-PI, Bayer HealthCare), which enabled the prepa-
ration of a liquid dosing form and henceforth systemic and even
intracystic injections. Importantly, systemic application circum-
vents the low oral absorption rate of albendazole and signiﬁcantly
elevates drug disposition (Lanusse et al., 1998). A proof of concept
trial in sheep infected with E. granulosus (n = 7) was performed,
which demonstrated that intracystic instillation without reaspira-
tion of albendazole sulfoxide signiﬁcantly decreased cyst size and
lead to death of all protoscoleces and daughter cysts 6 months
post-injection (Deger et al., 2000). Further studies in animals
and human subjects are warranted to evaluate if this therapeutic
approach could substitute the current lengthy oral albendazole
therapy.
Albendazole and mebendazole are currently the recommended
drugs for chemotherapy of echinococcosis; hence it is reasonable
that other benzimidazole derivatives are investigated. For instance
ﬂubendazole induced 90% reduction in cyst weight compared to
untreated mice infected with E. granulosus. This is particularly
remarkable, as lower quantities of ﬂubendazole were detected in
plasma and within the cysts compared to albendazole treatments,
suggesting a higher potency of ﬂubendazole (Ceballos et al., 2011).
Finally, it could be demonstrated that oxfendazole (60 mg/kg)
alone and in combination with praziquantel was able to decrease
protoscolex viability and reduce the diameter of liver and lung
cysts in sheep naturally infected with E. granulosus following
short-term treatment regimens (66 weeks) (Gavidia et al., 2010).
Notably, triclabendazole has shown potency in vitro and it would
be interesting to see if it is as successful as the other benzimidaz-
oles in vivo (Richter et al., 2013).6. Conclusion
We have summarized drug repurposing efforts against a wide
array of helminth infections. Drug repurposing is an important
strategy, in particular for these neglected tropical diseases since
drug discovery and development has languished in this ﬁeld.
Moreover, the time, effort and resources saved renders drug repur-
posing a smart and ethical choice, as it can result in faster and
more affordable access to new medicines.
Several dozen compounds were identiﬁed by systematically
searching the literature and presented in our review. This rather
low number mirrors the challenges helminth drug discovery
efforts still face. In vitro screens are often low throughput and cum-
bersome, as described for the T. muris assay (Wimmersberger et al.,
2013). Furthermore, we lack adequate animal models; prominent
examples are the two most important human ﬁlarials O. volvulus
and Wuchereria bancrofti, and the problematic L. loa. As such, it is
currently not possible to test drugs on these species directly
in vivo and most testing is conducted with infection models from
analogous animal ﬁlariasis infections, such as O. ochengi in cattle
(Geary and Mackenzie, 2011).Interestingly, only a few compound classes have been investi-
gated and several compounds have been studied against different
helminth species. Antimalarial and anticancer compounds were
most widely studied, though most of the successful anthelmintic
compounds still come from the antimalarial and veterinary ﬁelds.
Though most repurposed drugs still come from veterinary anthel-
mintic R & D, gradually compounds from ﬁelds such as antiproto-
zoal and anticancer research are being increasingly investigated
(Fig. 1). As mentioned in this review these drug classes were not
randomly selected but rather based on biological features (ﬂukes
have the same blood-feeding characteristic as Plasmodium spp.)
and possible drug targets (identiﬁcation of select protein kinases
as being essential to schistosome development) of these parasites.
With the availability of genomes, e.g. B. malayi or the L. loa genome,
it is the hope of many that compound libraries containing drugs’
known modes of action can be matched in silico against hel-
minth-speciﬁc gene targets, therefore providing potential drug
candidates. In addition, unsurprisingly the benzimidazole class of
compounds has been studied extensively. However, given that
there is known cross-resistance between the various benzimidaz-
oles in animal health, it is worth highlighting that a good clinical
candidate arising from this group would rather replace albenda-
zole and mebendazole than serve as backup.
Overall, disappointingly few compounds have been pursued
into clinical testing, which does little to alleviate the dry anthel-
mintic pipelines. A notable exception however is the trichuricidal
drug oxantel pamoate.
As public–private partnerships continue to expand, new com-
pounds and compound libraries have been made openly accessible.
For example, recently the Medicines for Malaria Venture made
available an open-source library consisting of 200 drug-like and
200 probe-like compounds, which was screened against S. mansoni
in vitro and in vivo. Though the in vivo results were moderate at
best, it did provide two potential new scaffolds to of interest: the
N,N0-diarylurea and 2,3-dianilinoquinoxaline derivatives (Ingram-
Sieber et al., 2014). This is an example illustrating that closer col-
laborations between different research ﬁelds would be of great
beneﬁt in the ﬁeld of drug discovery and development for helminth
diseases. More of such collaborations are needed to take bench
ﬁndings to the ﬁeld and to turn ﬁeld successes into affordable
and useable medicines.
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